Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. develops and commercializes medical technologies for the surgical market, including soft tissue repair, wound irrigation and bone fusion products used in operating rooms and sterile environments. Company news commonly covers financial results and guidance, sales and distribution activity, contracts for BIASURGE Advanced Surgical Solution, clinical and economic evidence for CellerateRX Surgical Powder, and product portfolio initiatives such as OsStic.
Coverage also includes conference presentations and business realignment disclosures, including the treatment of Tissue Health Plus as discontinued operations in Sanara's financial statements.
Sanara MedTech Inc. (NASDAQ: SMTI) reported its Q2 2024 results, marking its eleventh consecutive record revenue quarter. The company achieved $20.2 million in sales, a 28% increase from Q2 2023. Despite this growth, Sanara reported a net loss of $3.5 million, compared to a $1.9 million loss in Q2 2023. The increased loss was primarily due to higher SG&A costs, executive separation expenses, and acquisition costs.
Positive developments include Adjusted EBITDA of $0.6 million, improved from -$0.3 million in Q2 2023, and expanded market presence with products sold in over 1,100 facilities across 34 states. Sanara also secured a $55 million non-dilutive term loan to support growth initiatives and made key executive appointments to strengthen its management team.
Sanara MedTech Inc. (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies for surgical, chronic wound, and skincare markets, has announced the dates for its second quarter 2024 earnings release and conference call. The company will issue its earnings release on Monday, August 12, 2024, followed by a conference call on Tuesday, August 13, 2024, at 9:00 a.m. Eastern Time.
Investors can access the conference call via a toll-free number (888-506-0062 for domestic callers, 973-528-0011 for international callers) using the access code 984768. A telephonic replay will be available until August 27, 2024. Additionally, a live webcast of the call will be accessible on the company's website under the Investor Relations section, with a one-year online replay available after the broadcast.
Sanara MedTech Inc. announced its first quarter 2024 results, showcasing a tenth consecutive record revenue quarter with $18.5 million in sales. The company appointed new executive members, entered a $55.0 million non-dilutive term loan agreement, and saw its former CEO resign. Sanara also focused on increasing product usage, resulting in a 19% revenue increase. However, the company reported a net loss of $1.8 million for the quarter, primarily due to increased SG&A costs.
Sanara MedTech Inc., a medical technology company, announced the details for the release of its first quarter earnings for the period ending March 31, 2024. The company will issue its earnings release on May 13, 2024, and host a conference call on May 14, 2024, at 9:00 a.m. Eastern Time. Investors can access the call via phone or webcast.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.